The USTRx Act directs the U.S. government to challenge foreign pharmaceutical price controls it views as unfairly exploiting American drug innovation. The bill establishes a new Chief Pharmaceutical Trade Negotiator within the U.S. Trade Representative's office to conduct negotiations and enforcement actions against high-income countries that use price regulations the bill considers non-market-based. The Trade Representative must annually review and report to Congress on each wealthy nation's pharmaceutical policies, assessing whether they deny fair market access to American products, discourage innovation, or violate trade agreements. If violations are identified, the administration must submit a response plan within 30 days that may include initiating formal trade investigations. The bill reflects concern that other countries' government price-setting shifts pharmaceutical development costs to American patients and taxpayers while limiting incentives for global drug innovation.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.